The metabolic syndrome (MetS) is more strongly associated with cognitive impairment in the presence of inflammation. This suggests that the association of MetS with mild cognitive impairment (MCI) may vary with the etiology and the subtype of MCI. This study investigated the association between MetS with or without inflammation and MCI [amnestic (a-MCI) and nonamnestic (na-MCI)]. We studied a randomly selected sample of 1969 participants (ages 70 to 89 y) from Olmsted County, MN, using the Clinical Dementia Rating Scale, a neurologic evaluation, and neuropsychologic testing. Data for participants were reviewed for a diagnosis of normal cognition, MCI, or dementia. Clinical components of MetS were ascertained by interview and confirmed from the medical records; biochemical measurements were assayed from a blood draw. We compared 88 na-MCI cases and 241 a-MCI cases with 1640 cognitively normal participants. MetS was not associated with either na-MCI or a-MCI. High C-reactive protein (CRP; highest tertile vs lowest tertile) was associated with na-MCI [odds ratio (OR) = 1.85; 95% confidence interval (CI) = 1.05, 3.24] but not with a-MCI, after adjusting for sex, age, and years of education. The combination of MetS and high CRP (compared to no MetS and lowest CRP tertile) was associated with na-MCI (OR = 2.31; 95% CI = 1.07, 5.00), but not with a-MCI (OR = 0.96; 95% CI = 0.59, 1.54). The combined presence of MetS and high levels of inflammation is associated with na-MCI in this elderly cohort, and suggests etiologic differences in MCI subtypes.
T he metabolic or insulin resistance syndrome is a predictor of cardiovascular events including coronary heart disease (CHD) and stroke. 1, 2 The components of the metabolic syndrome (MetS), impaired fasting blood glucose, hypertension, abdominal obesity, hypertriglyceridemia, and low high-density lipoprotein, have all been associated with dementia in several studies. [3] [4] [5] The MetS may accelerate cognitive ageing through mechanisms related to microvascular and macrovascular damage, insulin resistance, inflammation, and adiposity. 6 Consistent with this hypothesis, the MetS has been associated with Alzheimer disease, 5 vascular dementia, 7 and cognitive decline. 8, 9 However, other investigators have reported no associations of the MetS with cognition. 10, 11 The inconsistency in study findings may relate to differences in assessment of cognitive impairment, criteria used for cognitive impairment, etiologic differences in mild cognitive impairment (MCI) subtypes, or age at which MetS is assessed. To our knowledge, the association between the MetS and MCI (defined by specified criteria at the time of evaluation) has not been assessed in the population-based setting. Our previous studies have shown associations of vascular risk factors including diabetes, 12 CHD, 13 and stroke 14 with na-MCI, but not with the amnestic subtype (a-MCI) which has been shown to have a stronger association with the apolipoprotein (ApoE) e4 allele, and with degenerative disease. Thus, we hypothesize that the MetS may be associated with the nonamnestic MCI subtype (na-MCI). This association of the MetS with na-MCI may occur through an inflammatory process with associated endothelial dysfunction. Finally, age at time of assessment of MetS, may influence the associations observed with MCI. In this study, we investigate the association of MetS with MCI overall and with MCI subtypes, and the potential interaction with inflammation in a population-based sample of elderly participants who have been well characterized for MCI using published criteria at the time of evaluation.
METHODS

Identification of Study Participants
The study was conducted as part of a populationbased study. The details of the study design and participant selection have been published previously. 15 Briefly we used the medical records-linkage system 16 to construct a sampling frame of all Olmsted County, MN, residents aged 70 to 89 years on October 1, 2004 . Of the eligible 4392 participants, 2719 (61.9%) agreed to participate in the study by telephone (n = 669) or in person (n = 2050), and 1673 declined participation. All participants provided informed, written consent prior to participation. Study participants underwent a blood draw; a nurse evaluation that included a risk factor assessment and administration of the Clinical Dementia Rating Scale to the participant and to an informant; a physician evaluation; and a neuropsychologic assessment using 9 cognitive tests to assess impairment in 4 cognitive domains: memory, executive function, language, and visuospatial skills. 15 
Criteria for MCI, Dementia, and Normal Cognition
All the data for each participant were reviewed by an expert panel of physicians, neuropsychologists, and nurses who evaluated the participant, for a diagnosis of MCI, normal cognition, or dementia by consensus. A diagnosis of MCI (cases) was made according to published criteria: cognitive concern by physician, nurse, or participant; impairment in 1 or more of the 4 cognitive domains; essentially normal functional activities; and absence of dementia. 17 Participants were classified as having a-MCI if the memory domain was impaired or na-MCI if there was no impairment in memory. A diagnosis of dementia was made according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. 18 Participants who did not receive a diagnosis of MCI or dementia were considered cognitively normal (controls) in accordance with published criteria. 17, 19 Assessment of the MetS Self-report of a physician diagnosis of diabetes and hypertension or treatment for these conditions was ascertained by interview. Participants were requested to bring bottles of all their current medications to the evaluation and from this, pharmacologic treatments for diabetes or hypertension were assessed. The diagnoses were also confirmed in the medical records-linkage system. 16 Weight was measured using an electronic balance, height was measured using a stadiometer, and blood pressure was measured in duplicate using a sphygmomanometer and averaged. Blood glucose levels at baseline were determined at the time of the blood draw after an overnight fast (for participants evaluated in the morning) and after a 4-hour fast for participants seen in the afternoon. Samples were aliquoted and stored at À 701C. Serum triglycerides, highdensity lipoprotein, and total cholesterol were measured from thawed frozen plasma or serum samples from the blood draw. 15 MetS was defined according to the criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, 2 the International Diabetes Federation, 20, 21 and the American Heart Association. 22 The criteria include presence of 3 or more of the following conditions: (1) use of antidiabetic agents (oral agents or insulin) or impaired fasting glucose Z110 mg/Dl; 2, 22 (2) treatment for hypertension, systolic blood pressure Z130 mm Hg, or diastolic blood pressure Z85 mm Hg;
(3) serum triglycerides Z150 mg/dL or treatment; (4) serum high-density lipoprotein <40 mg/dL for men or <50 mg/ dL for women; (5) obesity, defined as a body mass index (BMI; weight in kilograms divided by the height in meters squared) Z30 kg/m 2 based on the criterion used by the World Health Organization. 21, 23 This measure was a substitute for abdominal adiposity, the criterion used by National Cholesterol Education Program Adult Treatment Panel III (waist circumference Z50 inches in men and Z40 inches in women) 2 because abdominal adiposity was not measured at baseline. Since participants evaluated in the afternoon only had a 4-hour fast, a total cholesterol Z200 mg/dL was considered abnormal instead of triglyceride level Z150 mg/dL, 22 and a blood glucose level Z140 mg/dL was considered impaired. 24 Covariates Date of birth, sex, educational status, marital status, and current cigarette smoking status were assessed by interview. 15 A history of CHD and stroke were also assessed by interview and confirmed from the medical records-linkage system. 16 The presence of depressive symptoms was assessed by administration of the Neuropsychiatric Inventory Questionnaire to a spouse or to an informant of the participant. 25 C-reactive protein (CRP) was measured from the thawed frozen samples from the baseline blood draw, and ApoE e2, e3, e4 genotyping was performed using standard methods. 26 All study protocols were approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards.
Statistical Analyses
We compared participants with and without MCI using the nonparametric Wilcoxon rank sum test for continuous measures and a w 2 test for categorical variables. We used logistic regression models to estimate associations [odds ratios (ORs); 95% confidence intervals (CIs)] between MetS and MCI, adjusting for age in years, sex, and number of years of education. We repeated the analyses for MCI subtypes (na-MCI and a-MCI). In additional multivariable analyses we assessed potential confounding by ApoE genotype, CHD, depression, and stroke (fully adjusted model). We evaluated effect modification in stratified analyses across strata of age (70 to 79 y vs 80 to 89 y), sex, and years of education (<12 y vs Z12 y), and by explicitly incorporating interaction terms between MetS and the variable in the logistic regression models. Because of the reported interaction between MetS and inflammation in their association with cognitive decline, 8 and the observed associations of vascular risk factors with na-MCI among participants in the present study, we investigated the potential interaction between inflammation and MetS in their associations with MCI and its subtypes, with CRP as the measure of inflammation. To further explore this interaction, we categorized participants into 6 groups based both on presence or absence of MetS and on CRP tertile. We then assessed the OR (95% CI) of MCI for 5 of the categories compared to the reference group, which comprised participants with no MetS and CRP in the lowest tertile. In regard to criteria for MetS, we also defined an impaired fasting glucose as Z100 mg/dL as suggested in more recent literature and repeated the analyses using this cutpoint for impaired fasting glucose. However, the results were essentially the same and only the data using the cutpoint of Z110 mg/dL are reported. We also performed analyses to assess the association of MetS with MCI, adjusting for use of statins (yes or no) to assess confounding, and stratified by use of statins to assess possible interaction (effect modification). This is because participants with MetS are typically more likely to be receiving treatment with statins, which in turn, may reduce the burden of MetS and the impact of inflammation. 27 All analyses were performed using SAS version 8.0 software (SAS Institute, Cary, NC).
RESULTS
Of the 2050 who were evaluated in person, 1969 completed the face-to-face evaluation; 67 participants who were diagnosed with dementia based on the evaluation and 14 who did not complete the evaluation are not included in the present study. The characteristics of the 1969 participants are described in Table 1 ; 51% were male, 48% were <80 years old, and 53% had >12 years of education. The frequency of the MetS was 48% overall and did not differ between MCI cases and controls: 46% in participants with any MCI, and 48% in cognitively normal participants. Age, sex, years of education, history of CHD, stroke, depression, and ApoE e4 allele status were associated with MCI in unadjusted analyses; there was no difference in the use of statins ( Table 1 ). The frequency of a BMI Z30 kg/m 2 was lower in MCI cases than in controls (P = 0.04; Table 1 ), but there were no significant differences with regard to the remaining 4 individual components of the MetS. The frequency of MetS was higher among participants with na-MCI (51.1%) than among participants with a-MCI (44.4%), but neither differed significantly from cognitively normal participants (48.3%; Table 2 ). Compared to participants with a-MCI, participants with na-MCI had a nonsignificantly higher frequency of an impaired fasting glucose (P = 0.26), elevated blood pressure (P = 0.10), and BMI Z30 kg/m 2 (P = 0.19). Compared to cognitively normal participants, participants with na-MCI had a higher frequency of an elevated blood pressure (P = 0.06), whereas participants with a-MCI had a significantly lower frequency of a BMI Z30 kg/m 2 (P = 0.02). Participants with na-MCI had higher median CRP levels than participants with a-MCI (P = 0.02) and cognitively normal participants (P = 0.003; Table 2 ).
Participants with MetS had higher CRP levels than participants without MetS; this difference was statistically significant among cognitively normal participants, but not among participants with either MCI subtype (Fig. 1 In multivariable models, MetS was not significantly associated with MCI (combined a-MCI and na-MCI), a-MCI, or na-MCI; the point estimates were all close to the null ( Table 3 ). The point estimates and 95% CIs remained essentially the same in the fully adjusted models. With additional adjustment for use of statins, the ORs were unchanged ( Table 3 ). There were essentially no differences across strata based on statin use for association of MetS with all MCI, a-MCI, and na-MCI (data not reported). However, we did not have sufficient power to detect a significant effect modification for the association of MetS with na-MCI. High CRP (highest tertile vs lowest tertile) was associated with na-MCI (OR = 1.85; 95% CI = 1.05, 3.24) but not with a-MCI (OR = 1.07; 95% CI = 0.76, 1.52), after adjusting for sex, age, and years of education. When CRP (tertiles) and MetS were simultaneously assessed in the same model, the highest CRP tertile was significantly associated with na-MCI (OR = 1.84; 95% CI = 1.05, 3.23) but not with a-MCI (OR = 1.09; 95% CI = 0.77, 1.54); MetS was not associated with either na-MCI (OR = 1.03; 95% CI = 0.66, 1.61) or a-MCI zInformation was missing for 71 cognitively normal, 15 amnestic MCI, 1 nonamnestic MCI. Nonamnestic MCI were significantly different from amnestic MCI (P = 0.016), and from cognitively normal (P = 0.003).
BMI indicates body mass index; DM, diabetes mellitus; DBP, diastolic blood pressure; HDL, high-density lipoprotein; MCI, mild cognitive impairment; SBP, systolic blood pressure; Q1, 25th percentile; Q3, 75th percentile; %, is in nonmissing participants.
(OR = 0.90; 95% CI = 0.68, 1.20). The interactions between MetS and inflammation, as measured by tertiles of CRP, were not statistically significant for all MCI (P = 0.872), for a-MCI (P = 0.877), or na-MCI (P = 0.435). When associations of MCI with the combined categories of inflammation (based on CRP tertiles) and MetS were examined, the combination of MetS and high CRP (compared to no MetS and lowest CRP tertile; the reference group) was associated with na-MCI (OR = 2.31; 95% CI = 1.07, 5.00; P = 0.03), but not with a-MCI (OR = 0.96; 95% CI = 0.59, 1.54; Table 4 ). However, given that the interaction between MetS and CRP did not reach significance, we cannot exclude the possibility that this difference predominantly reflects that main effect of CRP that we have observed.
DISCUSSION
In our population-based sample of 70 to 89-year-olds, participants with MetS and high levels of inflammation had a 2.3-fold elevated OR of na-MCI. Given several prior reports of an interaction between levels of inflammatory response markers and MetS, our finding was not completely unexpected. 8, 9, 28 Although we found no overall association between MetS and MCI, we have previously observed in this cohort that vascular phenomena such as diabetes, 12 stroke, 14 and CHD 13 are associated with na-MCI rather than with a-MCI, the MCI subtype that is typically associated with Alzheimer's disease (AD). Thus, we have extended prior observations by others in demonstrating that in the presence of inflammation, the MetS may be more likely to be associated with the form of cognitive , ee2e3, e3e3) . zWith additional adjustment for use of statins, the estimates remained essentially the same: OR = 1.01 (95% CI = 0.90, 1.14) for all MCI, OR = 0.96 (95% CI = 0.84, 1.10) for a-MCI, and OR = 1.11 (95% CI = 0.92, 1.35) for na-MCI.
ApoE indicates apolipoprotein; CI, confidence interval; MCI, mild cognitive impairment; OR, odds ratio. impairment, na-MCI, that may be more closely linked to cerebrovascular disease. 29 The observation that the combined presence of MetS and a high level of inflammation is associated with na-MCI but not with a-MCI, is novel. Other investigators have reported associations of MetS with cognitive impairment among participants with high levels of inflammation. 8, 9, 28 However, these studies have typically not distinguished between cognitive impairment subtypes. In 2 prospective cohort studies, participants with MetS and high levels of inflammation had a greater cognitive decline during followup 8 or an increased risk of cognitive impairment 9,28 compared to participants with low levels of inflammation. Thus, the effects of the MetS on cognition in elderly persons may be mediated directly through inflammation, or indirectly through effects of inflammation on cerebral atherosclerosis and endothelial dysfunction. 6, 22 Consistent with the observed modifying role of inflammation, it has been suggested that the effect of including CRP in criteria for MetS in predicting atherosclerotic vascular disease should be investigated. 30 The lack of an association of MetS with a-MCI is inconsistent with the purported role of a-MCI as a prodromal stage for AD and the positive association of vascular risk factors with AD. This inconsistency may, in part, be due to certain reasons. The association of ApoE e4 allele with a-MCI may be stronger and evident earlier in the pathologic disease process than the effect of vascular diseases. This is confirmed by the significant association between a-MCI and presence of an ApoE e4 allele (OR = 1.68; 95% CI = 1.23, 2.30) in the present study. 14 In addition, ApoE e4 allele has been associated with lower levels of inflammation. 31, 32 These factors may mitigate against observing an association of MetS with a-MCI in the earlier stages of the disease or until there is more severe vascular disease as in AD. Participants with a-MCI in this study were at the very mild end of the disease spectrum; the mean CDR sum of boxes score was only 0.5. Thus, as with other studies that have not observed a predictive role of MetS for vascular outcomes in the short term, 22,33 a positive association of MetS or vascular risk factors with a-MCI, or a-MCI progression to AD, may be observed in the longer term. Thus, although vascular risk factors may be associated with both a-MCI and na-MCI, the association with a-MCI may be observed at a more severe stage of MCI.
We did not observe an association between MetS and MCI overall. This lack of an association when MCI subtype or inflammation is not taken into account may be related to the older age of participants in the present study, and is consistent with similar studies conducted among older participants. In the Leiden 85-Plus Study (all aged 85 y at baseline), there were no differences between participants with and without the MetS for any of the cognitive tests at baseline 34 ; however, during follow-up there was a decelerated decline in cognition among participants with MetS at baseline compared to participants with no MetS. 34 Similarly, among participants with a mean age of 79 years, participants with MetS had significantly better cognitive function compared to participants without MetS (OR = 0.37; 95% CI = 0.15, 0.91). 35 Alternately, significant positive associations between MetS and cognitive impairment have been reported in cohorts that were younger than participants in the present study. 8, 9, 28, 36 Typically, these studies also did not distinguish between MCI subtypes or specific cognitive domains. In the Longitudinal Aging Study Amsterdam (aged 65 to 88 y), MetS was associated with cognitive impairment crosssectionally. 28 In another prospective cohort (mean age 71 y), participants with MetS at baseline had a greater cognitive decline than participants without MetS during follow-up. 8 In the Health, Aging, and Body Composition Study (mean age 74 y), there were no significant differences in cognitive scores between participants with and without MetS at baseline, but the MetS was associated with a 20% increased risk of cognitive impairment during follow-up. 9 In the Singapore Longitudinal Aging Studies (mean age approximately 55 y), the MetS was significantly associated with a decline in cognition. 37 Together, these studies suggest that the association between the MetS and cognitive function may vary with age at ascertainment of the MetS. Components of the MetS in mid-life are a risk factor for late-life dementia or accelerated cognitive impairment, 38, 39 yet, when assessed in elderly participants, these conditions are associated with either a decelerated cognitive decline or have no association with late-life cognitive impairment. 10, 11, 40 The decline in weight prior to dementia onset may represent adverse health conditions that may promote cognitive impairment or dementia. 41 In contrast, high BMI in elderly persons may reflect well-being, consistent with the hypothesis that some forms of obesity may not be associated with insulin resistance and, therefore, may not increase the risk of cognitive impairment. 37 Similarly, elevated blood pressure in older persons may prevent cerebral hypoperfusion and, thereby, may protect against cognitive impairment. 40 It is also possible that the perceived beneficial effects of MetS or its components on cognition in the elderly may be due to survival bias wherein participants with MetS or its components who are at greater risk for cognitive impairment have greater mortality, and do not survive to an older age.
There are several strengths to our study. The population-based design reduces the potential for selection bias. The prospective characterization of participants for MCI using previously published specified criteria reduces the potential for misclassification of the MCI diagnosis, as could occur from retrospective application of MCI criteria to previously collected data on cognition, or from the use of nonestablished criteria for MCI. The medical recordslinkage system allowed us to validate self-report of diabetes and hypertension, thereby minimizing misclassification regarding presence of the MetS. These findings in an older population-based cohort add to the current literature suggesting that among the elderly, MetS or its components may not necessarily have an adverse impact on cognition. Future follow-up of the cohort will enable us to determine whether the combined presence of inflammation and MetS at baseline is associated with cognitive decline during follow-up, incident na-MCI, or whether, in contrast, MetS without inflammation has no association with cognitive decline or contributes to a decelerated cognitive decline as suggested. 34 Limitations of our study that should be noted include the cross-sectional assessment of the association of MetS with MCI; this precludes our ability to assess causality. There is potential for nonparticipation bias if participants with MetS and cognitive impairment were less likely to participate in the study. To address potential nonparticipation bias, we used a propensity scores approach and medical record information abstracted from the medical records-linkage system for participants and nonparticipants, to assess potential nonparticipation bias. This approach takes into account the characteristics of nonparticipants 42 and assigns higher weights for participants who have characteristics similar to nonparticipants in logistic regression models. The propensity-adjusted estimates for this study were the same as the unadjusted estimates, suggesting an absence of nonparticipation bias on our findings (these results are not reported). Finally, the study was conducted among an older cohort of primarily caucasian participants; therefore, caution should be exercised in applying the findings to participants not represented in the study.
